IMPROVING THE MEDICAL ABORTION REGIMEN
- Autores: PLOTKO E.E1,2
-
Afiliações:
- Ural State Medical Academy
- «Harmony» Medical Center
- Edição: Nº 3 (2013)
- Páginas: 107-111
- Seção: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247003
- ID: 247003
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Objective. To determine the medical and social characteristics of women undergoing termination of pregnancy earlier than 6 weeks and to comparatively evaluate the efficacy and safety of different mifepristone doses for medical abortion (МА). Subjects and methods. A prospective comparative study of the efficacy of different mifepristone doses (600 and 200 mg) for a MA regimen was conducted in 337 and 130 women undergoing termination pregnancy less than 6 weeks’ gestation, respectively. Sonography, vaginal smear bacterioscopy, and in some cases, if indicated, vacuum aspiration, pathomorphological examination of the uterine material were performed. Results. The medico-social portrait of women preferring a reduced mifepristone dose is presented with their late reproductive age (35-43 years), blue-collarjobs, unemployed, mainly legally married women, and parous women who had fewer artificial abortions and a history of MA. Previous genital inflammatory diseases and reproductive losses were determinants in women who are a group at high-risk for post-abortion infectious complications (incomplete abortion and endo-metritis), However, the frequency of complications of MA did not depend on the used dose of mifepristone. The low frequency of complications of MA was ascertained to be associated with a package of preventive measures, such as sanitation of the lower genital tract, ultrasound monitoring of the quality of an abortion.
Palavras-chave
Texto integral
Bibliografia
- Jones R.K., Kooistra K. Abortion incidence and access to services in the United States, 2008. Perspect. Sex. Reprod. Health. 2011; 43(1): 41-50.
- Raymond E.G., Shannon C., Weaver M.A., Winikoff B. First-trimester medical abortion with mifepristone 200 mg and misoprostol: a systematic review. Contraception. 2013; 87(1): 26-37.
- Winikoff B., Sheldon W. Use of medicines changing the face of abortion. Int. Perspect. Sex. Reprod. Health. 2012; 38(3): 164-6.
- Dalvie S. Secretariat, Asia Safe Abortion Partnership, Mumbai, India, personal communication. July 2, 2012.
- Ngoc N.T., Blum J., Raghavan S., Nga N.T., Dabash R., Diop A., Winikoff B. Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone. Contraception. 2011; 83(5): 410-7.
- World Health Organization. Safe abortion: technical and policy guidance for health systems. 2nd ed. Geneva: World Health Organization; 2012.
- Schaff E.A., Fielding S.L., Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception. 2002; 66(4): 247-50.
- Chawdhary R., Rana A., Pradhan N. Mifepristone plus vaginal misoprostol vs vaginal misoprostol alone for medical abortion in gestation 63 days or less in Nepalese women: a quasirandomized controlled trial. J. Obstet. Gynaecol. Res. 2009; 35(1): 78-85.
- Boersma A.A., Meyboom-de Jong B., Kleiverda G. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in a general practice in Curagao. Eur. J. Contracept. Reprod. Health Care. 2011; 16(2): 61-6.
- Chong E., Tsereteli T., Nguyen N.N., Winikoff B. A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion. Contraception. 2012; 86(3): 251-6.
- Fernandez M.M., Coeytaux F., de Leon R.G., Harrison D.L. Assessing the global availability of misoprostol. Int. J. Gynaecol. Obstet. 2009; 105(2): 180-6.
- Kulier R., Kapp N., Gtilmezoglu A.M., Hofmeyr G.J., Cheng L., Campana A. Medical methods for first trimester abortion. Cochrane Database Syst. Rev. 2011; (11): CD002855.
- Lievre M., Sitruk-Ware R. Meta-analysis of 200 or 600 mg mifepristone in association with two prostaglandins for termination of early pregnancy. Contraception. 2009; 80(1): 95-100.